|
|
Interactions
with Carnitine (L-Carnitine) | |
Azidothymidine
(AZT);
Zidovudine
In an in vitro study with human muscle tissue, the addition of L-carnitine (5
mM) to muscle cultures pretreated with AZT (0.0027 to 135 mcg/mL) preserved the
integrity and volume of mitochondria (Semino-Mora et al. 1994). Coadministration
of L-carnitine to AIDS patients on AZT therapy may prevent the development of
myotoxicity typically associated with this
drug. Doxorubicin
In one study, isolated cardiac myocytes and rat mitochondria perfused with
doxorubicin (5 mM) treatment with L-carnitine reversed the cardiotoxic affects
associated with the drug without affecting therapeutic effects (Sayed-Ahmed et
al. 1999). In another study with mice, carnitine significantly decreased cardiac
toxicity at both acute high and chronic intermittent low doses (Alberts et al.
1978). The cardiotoxic effects of doxorubicin were not observed in children
treated with a combination of doxorubicin (30 to 60 mg/kg) and carnitine (1 to 2
g) (Chavez et al. 1997). |
|
|
References |
|
Alberts DS, Peng YM, Moon TE, Bressler R. Carnitine prevention of adriamycin
toxicity in mice. Biomed. 1978;29(8):265-268.
Chavez GA, Hernandez IM, Ollarve CF, Natera YM. Myocardial protection by
L-carnitine in children treated with adriamycin. Rev Lat Cardiol.
1997;18:208-214.
Sayed-Ahmed MM, Shaarawy S, Shouman SA, Osman AM. Reversal of
doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacol
Res. 1999;39(4):289-295.
Semino-Mora MC, Leon-Monzon ME, Dalakas MC. Effect of L-carnitine on the
zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents
the myotoxicity of AZT in vitro. Lab Invest.
1994;71(1):102-112. |
|
Copyright © 2000 Integrative Medicine
Communications This publication contains
information relating to general principles
of medical care that should not in any event be construed as specific
instructions for individual patients. The publisher does not accept any
responsibility for the accuracy of the information or the consequences arising
from the application, use, or misuse of any of the information contained herein,
including any injury and/or damage to any person or property as a matter of
product liability, negligence, or otherwise. No warranty, expressed or implied,
is made in regard to the contents of this material. No claims or endorsements
are made for any drugs or compounds currently marketed or in investigative use.
The reader is advised to check product information (including package inserts)
for changes and new information regarding dosage, precautions, warnings,
interactions, and contraindications before administering any drug, herb, or
supplement discussed herein. | |